Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Aciba...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2014-08, Vol.31 (8), p.74, Article 74 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 74 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 31 |
| creator | Mutlu, Hasan Gündüz, Şeyda Karaca, Halit Büyükçelik, Abdullah Cihan, Yasemin Benderli Erden, Abdülsamet Akca, Zeki Coşkun, Hasan Şenol |
| description | In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (
p
= 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (
p
= 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (
p
= 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM. |
| doi_str_mv | 10.1007/s12032-014-0074-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1550643212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3391052991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-7445bb9fe72c11d19e4cd7f3b071438586d879186ec4f10a1ae3afd3280f2f323</originalsourceid><addsrcrecordid>eNp1UUuLFDEQDqK4D_0BXiTgOZrKY9LtTRYfCwt72F3w1qTT1TNZku42SY_Mb_JPmmFW8eKhSBX5Hkl9hLwB_h44Nx8yCC4F46BYHRVrn5Fz0LplIOH789pLbRjXG35GLnJ-5FyAFu1LciZUqxsN5pz8ukM3TwMLfkK6xeh8sX3tWW8zDtTtMM5lh8kuB5pw6yNOmfq4pHmPtFayIVDJDmgTzWva-70NNNmC1E90scXjVDL96cuORhv8drJToUvAtRJpxHwUD36O9iO1NK6heFcZmKpZSXNe0BVfnXJZh8Mr8mK0IePrp_OSPHz5fH_1jd3cfr2--nTDnDSiMKOU7vt2RCMcwAAtKjeYUfbcgJKNbjZDY1poNujUCNyCRWnHQYqGj2KUQl6Sdyfd-ssfK-bSPc5rmqplV7fLN0oKOKLghHL1nTnh2C3JR5sOHfDuGE93iqer8XTHeLq2ct4-Ka99xOEv408eFSBOgFyvpi2mf6z_q_obQoyfcQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1550643212</pqid></control><display><type>article</type><title>Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Mutlu, Hasan ; Gündüz, Şeyda ; Karaca, Halit ; Büyükçelik, Abdullah ; Cihan, Yasemin Benderli ; Erden, Abdülsamet ; Akca, Zeki ; Coşkun, Hasan Şenol</creator><creatorcontrib>Mutlu, Hasan ; Gündüz, Şeyda ; Karaca, Halit ; Büyükçelik, Abdullah ; Cihan, Yasemin Benderli ; Erden, Abdülsamet ; Akca, Zeki ; Coşkun, Hasan Şenol</creatorcontrib><description>In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (
p
= 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (
p
= 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (
p
= 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0074-9</identifier><identifier>PMID: 24958517</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject><![CDATA[Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cisplatin - administration & dosage ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Female ; Glutamates - administration & dosage ; Glutamates - therapeutic use ; Guanine - administration & dosage ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hematology ; Humans ; Internal Medicine ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Mesothelioma - drug therapy ; Mesothelioma - mortality ; Mesothelioma - pathology ; Mesothelioma, Malignant ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Pemetrexed ; Retrospective Studies ; Survival Rate ; Treatment Outcome]]></subject><ispartof>Medical oncology (Northwood, London, England), 2014-08, Vol.31 (8), p.74, Article 74</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-7445bb9fe72c11d19e4cd7f3b071438586d879186ec4f10a1ae3afd3280f2f323</citedby><cites>FETCH-LOGICAL-c372t-7445bb9fe72c11d19e4cd7f3b071438586d879186ec4f10a1ae3afd3280f2f323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0074-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0074-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24958517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mutlu, Hasan</creatorcontrib><creatorcontrib>Gündüz, Şeyda</creatorcontrib><creatorcontrib>Karaca, Halit</creatorcontrib><creatorcontrib>Büyükçelik, Abdullah</creatorcontrib><creatorcontrib>Cihan, Yasemin Benderli</creatorcontrib><creatorcontrib>Erden, Abdülsamet</creatorcontrib><creatorcontrib>Akca, Zeki</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><title>Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (
p
= 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (
p
= 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (
p
= 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.</description><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Female</subject><subject>Glutamates - administration & dosage</subject><subject>Glutamates - therapeutic use</subject><subject>Guanine - administration & dosage</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma - mortality</subject><subject>Mesothelioma - pathology</subject><subject>Mesothelioma, Malignant</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Pemetrexed</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1UUuLFDEQDqK4D_0BXiTgOZrKY9LtTRYfCwt72F3w1qTT1TNZku42SY_Mb_JPmmFW8eKhSBX5Hkl9hLwB_h44Nx8yCC4F46BYHRVrn5Fz0LplIOH789pLbRjXG35GLnJ-5FyAFu1LciZUqxsN5pz8ukM3TwMLfkK6xeh8sX3tWW8zDtTtMM5lh8kuB5pw6yNOmfq4pHmPtFayIVDJDmgTzWva-70NNNmC1E90scXjVDL96cuORhv8drJToUvAtRJpxHwUD36O9iO1NK6heFcZmKpZSXNe0BVfnXJZh8Mr8mK0IePrp_OSPHz5fH_1jd3cfr2--nTDnDSiMKOU7vt2RCMcwAAtKjeYUfbcgJKNbjZDY1poNujUCNyCRWnHQYqGj2KUQl6Sdyfd-ssfK-bSPc5rmqplV7fLN0oKOKLghHL1nTnh2C3JR5sOHfDuGE93iqer8XTHeLq2ct4-Ka99xOEv408eFSBOgFyvpi2mf6z_q_obQoyfcQ</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Mutlu, Hasan</creator><creator>Gündüz, Şeyda</creator><creator>Karaca, Halit</creator><creator>Büyükçelik, Abdullah</creator><creator>Cihan, Yasemin Benderli</creator><creator>Erden, Abdülsamet</creator><creator>Akca, Zeki</creator><creator>Coşkun, Hasan Şenol</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140801</creationdate><title>Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study</title><author>Mutlu, Hasan ; Gündüz, Şeyda ; Karaca, Halit ; Büyükçelik, Abdullah ; Cihan, Yasemin Benderli ; Erden, Abdülsamet ; Akca, Zeki ; Coşkun, Hasan Şenol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-7445bb9fe72c11d19e4cd7f3b071438586d879186ec4f10a1ae3afd3280f2f323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Female</topic><topic>Glutamates - administration & dosage</topic><topic>Glutamates - therapeutic use</topic><topic>Guanine - administration & dosage</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma - mortality</topic><topic>Mesothelioma - pathology</topic><topic>Mesothelioma, Malignant</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Pemetrexed</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mutlu, Hasan</creatorcontrib><creatorcontrib>Gündüz, Şeyda</creatorcontrib><creatorcontrib>Karaca, Halit</creatorcontrib><creatorcontrib>Büyükçelik, Abdullah</creatorcontrib><creatorcontrib>Cihan, Yasemin Benderli</creatorcontrib><creatorcontrib>Erden, Abdülsamet</creatorcontrib><creatorcontrib>Akca, Zeki</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mutlu, Hasan</au><au>Gündüz, Şeyda</au><au>Karaca, Halit</au><au>Büyükçelik, Abdullah</au><au>Cihan, Yasemin Benderli</au><au>Erden, Abdülsamet</au><au>Akca, Zeki</au><au>Coşkun, Hasan Şenol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>31</volume><issue>8</issue><spage>74</spage><pages>74-</pages><artnum>74</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (
p
= 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (
p
= 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (
p
= 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24958517</pmid><doi>10.1007/s12032-014-0074-9</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2014-08, Vol.31 (8), p.74, Article 74 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_1550643212 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antimetabolites, Antineoplastic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Glutamates - administration & dosage Glutamates - therapeutic use Guanine - administration & dosage Guanine - analogs & derivatives Guanine - therapeutic use Hematology Humans Internal Medicine Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medicine Medicine & Public Health Mesothelioma - drug therapy Mesothelioma - mortality Mesothelioma - pathology Mesothelioma, Malignant Middle Aged Oncology Original Paper Pathology Pemetrexed Retrospective Studies Survival Rate Treatment Outcome |
| title | Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T10%3A42%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second-line%20gemcitabine-based%20chemotherapy%20regimens%20improve%20overall%203-year%20survival%20rate%20in%20patients%20with%20malignant%20pleural%20mesothelioma:%20a%20multicenter%20retrospective%20study&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Mutlu,%20Hasan&rft.date=2014-08-01&rft.volume=31&rft.issue=8&rft.spage=74&rft.pages=74-&rft.artnum=74&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0074-9&rft_dat=%3Cproquest_cross%3E3391052991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1550643212&rft_id=info:pmid/24958517&rfr_iscdi=true |